» Articles » PMID: 36585031

Sudan Virus Disease Outbreak in Uganda: Urgent Research Gaps

Overview
Journal BMJ Glob Health
Specialty Public Health
Date 2022 Dec 30
PMID 36585031
Authors
Affiliations
Soon will be listed here.
Abstract

The Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued to spread to several regions including the capital. The ongoing transmission, uncertain case numbers and no licensed vaccine or therapeutics available are a cause for concern. We searched four databases for SUDV research using the search terms "SUDV", "Sudan Virus" and "Ebola Sudan". Our analysis identified only 20 SUDV research studies. Most were implemented in the USA and only one in Uganda. Nine studies were on therapeutics, eight on vaccines, one on diagnostics, one in one health and one in social science. Our data highlight a lack of SUDV research and an urgent need for investment to identify an effective vaccine, and optimal supportive care and therapeutic strategies for all at risk groups as a key research priority. Research investments should be prioritised into vaccines and treatment strategies that will be accessible to high-risk populations in affected regions during the outbreak, to protect populations, improve individual outcomes and facilitate outbreak control.

Citing Articles

Sudan Virus Persistence in Immune-Privileged Organs of Nonhuman Primate Survivors.

Beavis B, Liu J, Zumbrun E, Bryan A, Babka A, Twenhafel N Emerg Infect Dis. 2025; 31(2):275-280.

PMID: 39983711 PMC: 11845127. DOI: 10.3201/eid3102.240983.


Cryo-EM structure of Sudan ebolavirus glycoprotein complexed with its human endosomal receptor NPC1.

Bu F, Ye G, Turner-Hubbard H, Herbst M, Liu B, Li F Commun Biol. 2025; 8(1):156.

PMID: 39894818 PMC: 11788421. DOI: 10.1038/s42003-025-07613-y.


Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.

Bu F, Ye G, Morsheimer K, Mendoza A, Turner-Hubbard H, Herbst M PLoS Pathog. 2024; 20(12):e1012817.

PMID: 39715280 PMC: 11723632. DOI: 10.1371/journal.ppat.1012817.


Stigma among ebola disease survivors in Mubende and Kassanda districts, Central Uganda, 2022.

Zalwango M, Paige S, Migisha R, Nakafeero Simbwa B, Nsubuga E, Asio A PLOS Glob Public Health. 2024; 4(12):e0003272.

PMID: 39680556 PMC: 11649098. DOI: 10.1371/journal.pgph.0003272.


Community perspectives of Ebola Viral Disease in high-risk transmission border regions of Tanzania: a qualitative inquiry.

Metta E, Mohamed H, Kusena P, Nyamhanga T, Bahuguna S, Kakoko D BMC Public Health. 2024; 24(1):2766.

PMID: 39390413 PMC: 11465839. DOI: 10.1186/s12889-024-20305-2.


References
1.
Lang T . Ebola: Embed research in outbreak response. Nature. 2015; 524(7563):29-31. DOI: 10.1038/524029a. View

2.
Broadhurst M, Brooks T, Pollock N . Diagnosis of Ebola Virus Disease: Past, Present, and Future. Clin Microbiol Rev. 2016; 29(4):773-93. PMC: 5010747. DOI: 10.1128/CMR.00003-16. View

3.
Kozlov M . Ebola outbreak in Uganda: how worried are researchers?. Nature. 2022; . DOI: 10.1038/d41586-022-03192-8. View

4.
Ledgerwood J, DeZure A, Stanley D, Coates E, Novik L, Enama M . Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2014; 376(10):928-938. DOI: 10.1056/NEJMoa1410863. View

5.
Emperador D, Mazzola L, Trainor B, Chua A, Kelly-Cirino C . Diagnostics for filovirus detection: impact of recent outbreaks on the diagnostic landscape. BMJ Glob Health. 2019; 4(Suppl 2):e001112. PMC: 6407532. DOI: 10.1136/bmjgh-2018-001112. View